Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan. (PubMed, Mod Rheumatol) - Aug 30, 2026 - "Baricitinib showed sustained effectiveness and retention, including in patients with D2T RA; early improvements in pain and fatigue were predictive of CDAI disease remission during the 24-month follow-up."
Journal • Observational data • Real-world evidence • Fatigue • Immunology • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology
|
|
Izumi Sato; Kei Ikeda; Naoto Tsujimoto; Taisuke Kojima; Yuko Kaneko
|